Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a stronger antibiotic dose keep cellulitis patients out of hospital?

NCT ID NCT05852262

Disease control Sponsor: Ottawa Hospital Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times

Summary

This study tests whether a higher dose of the oral antibiotic cephalexin can better treat cellulitis, a common skin infection, in adults visiting the emergency room. About 446 participants will receive either a high or standard dose to see if it reduces the need for changing antibiotics or hospitalization. The goal is to improve treatment success and lower healthcare costs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

454 people

The number who actually took part.

Started

Aug 2023

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Adults (age ≥18 years) diagnosed with non-purulent cellulitis and determined by the treating emergency physician to be eligible for outpatient oral antibiotics. Exclusion Criteria: 1. Age \<18 years; 2. Patient already taking oral antibiotics; 3. Treating physician decides IV antibiotics are required; 4. Abscess requiring an incision and drainage procedure; 5. Known prior skin or soft tissue infection secondary to methicillin-resistant Staphylococcus aureus (MRSA); 6. Cellulitis secondary to a human or animal bite wound; 7. Penetrating wound or water exposure resulting in cellulitis; 8. Surgical site infection; 9. Patient found at a follow up visit to have an alternative, non-infectious etiology (e.g., deep vein thrombosis); 10. bilateral symptoms (e.g., both legs involved); 11. Malignancy and currently being treated with chemotherapy; 12. Solid organ or bone marrow transplant recipient; 13. Renal impairment with an estimated glomerular filtration rate \<30 mL/min documented on the health record at any time within the past three months; 14. Allergy to cephalosporins or history of anaphylaxis to penicillin; 15. Inability to provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cellulitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cellulitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cellulitis

Contacts and locations

Locations

  • Enfant-Jésus Hospital

    Québec, Quebec, Canada

  • Health Sciences North

    Greater Sudbury, Ontario, P3E 2H2, Canada

  • Hôpital du Sacré-Cœur de Montréal

    Montreal, Quebec, Canada

  • Kingston Health Sciences Centre

    Kingston, Ontario, Canada

  • London Health Sciences Centre

    London, Ontario, Canada

  • Queen Elisabeth II Health Sciences Centre

    Halifax, Nova Scotia, Canada

  • Sinai Health System

    Toronto, Ontario, Canada

  • South Health Campus

    Calgary, Alberta, Canada

  • The Ottawa Hospital

    Ottawa, Ontario, K1Y 4E9, Canada

  • Thunder Bay Health Sciences Centre

    Thunder Bay, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.